FDA approves Agilent PD-L1 test for four new cancer types

The FDA approved Agilent's PD-L1 test for four additional cancer types, expanding its use on the Dako Omnis platform. This approval allows the test to identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma who may be eligible for Merck's KEYTRUDA treatment. The test, developed with Merck, was previously available on a different platform for these indications.